FDA OKs Elacestrant for ESR1+ Advanced, Metastatic Breast Cancer
The US Food and Drug Administration approved elacestrant (Orserdu, Stemline Therapeutics, Inc) for postmenopausal women or men with ER-positive, HER2-negative, ...
© Medical News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.